Version history

{
  "content_md": "# ADRB2 Gene\n\n<div class=\"infobox infobox-gene\">\n  <table>\n    <tr><th colspan=\"2\" style=\"background:#4477AA; color:white;\">ADRB2</th></tr>\n    <tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>\n    <tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>\n    <tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>\n    <tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>\n    <tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>\n    <tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>\n    <tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>\n    <tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>\n  </table>\n</div>\n\n## Overview\n\n**ADRB2** encodes the **β2-adrenergic receptor** (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].\n\nThe β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].\n\n## Molecular Biology and Structure\n\n### Gene Organization\n\nThe ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:\n\n- **TATA box**: Core promoter element\n- **CRE elements**: cAMP response elements for regulated expression\n- **AP-1 sites**: Responsive to growth factors and cytokines\n- **GRE**: Glucocorticoid response elements\n- **NF-κB elements**: Allows inflammatory regulation\n\nMultiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].\n\n### Protein Structure\n\nThe β2-adrenergic receptor has classical GPCR architecture:\n\n- **N-terminal extracellular domain** (1-39 aa): Contains two N-linked glycosylation sites\n- **Transmembrane domains** (TM1-TM7): Seven α-helices forming the ligand-binding pocket\n- **Extracellular loops** (ECL1-ECL3): ECL2 contains a conserved disulfide bond\n- **Intracellular loops** (ICL1-ICL3): ICL3 is the primary G protein coupling domain\n- **C-terminal tail** (342-413 aa): Contains serine/threonine phosphorylation sites\n\nThe ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:\n- Asp113 in TM3 (counterion for catecholamine amine)\n- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)\n- Phe282 (hydrophobic interactions with aromatic ring)\n\n### Splice Variants\n\nMultiple splice variants of ADRB2 have been described:\n- **β2-AR1**: Full-length 413 aa (predominant)\n- **β2-AR2**: Alternative C-terminus\n- **Truncated variants**: May have distinct signaling properties\n\n## Signaling Pathways\n\n### Primary Gs-cAMP Pathway\n\nUpon agonist binding:\n\n1. **Conformational change** activates Gs protein\n2. **Gαs-GTP** stimulates adenylyl cyclase\n3. **cAMP production** increases\n4. **PKA activation** leads to substrate phosphorylation\n5. **Physiological effects** on muscle relaxation, glycogenolysis, gene transcription\n\n### Alternative Gi/o Coupling\n\nIn some cell types, β2-AR couples to Gi/o:\n- **Inhibition of adenylyl cyclase** reduces cAMP\n- **βγ subunits** activate PI3K pathways\n- **Cell-type specificity** determines coupling preference\n\n### β-Arrestin Pathways\n\nβ2-AR signals through β-arrestins independently of G proteins:\n\n- **ERK1/2 activation** via β-arrestin scaffolds\n- **Akt activation** through similar mechanisms\n- **Receptor internalization** and recycling\n- **Biased signaling** potential for drug design\n\n### Receptor Dynamics\n\nβ2-AR exhibits unique properties:\n\n- **Constitutive activity**: Some basal signaling without agonist\n- **Inverse agonism**: Some ligands reduce baseline activity\n- **Allosteric modulators**: Bind at distinct sites\n- **Oligomerization**: May form heteromers with other GPCRs\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\n#### Memory Consolidation\n\nβ2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:\n\n- **Hippocampal LTP**: β2-AR activation enhances long-term potentiation\n- **Memory enhancement**: Agonists improve consolidation in multiple paradigms\n- **cAMP/PKA/CREB pathway**: Required for consolidation effects\n- **Time window**: Effects greatest during post-training period\n\nThe noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.\n\n#### Amyloid Pathology\n\nβ2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:\n\n- **APP processing**: cAMP can influence α-secretase activity\n- **Aβ production**: Effects are context-dependent\n- **Synaptic protection**: β2-AR activation protects against Aβ-induced synaptic dysfunction\n- **Neuronal survival**: Anti-apoptotic signaling through PI3K/Akt\n\n#### Neuroinflammation\n\nβ2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:\n\n- **Microglial inhibition**: β2-AR activation reduces pro-inflammatory cytokine release\n- **TNF-α suppression**: Reduces microglial activation\n- **IL-1β and IL-6**: Suppressed by β2-agonists\n- **Therapeutic potential**: Reduces neuroinflammation in AD models\n\n#### Genetic Associations\n\nSeveral studies link ADRB2 variants to AD risk[@mittal2017]:\n\n- **Functional polymorphisms** may alter receptor signaling\n- **Population-specific effects** observed in different cohorts\n- **Gene-environment interactions** with lifestyle factors\n\n### Parkinson's Disease\n\n#### Neuroprotection\n\nβ2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:\n\n- **Dopaminergic neuron survival**: Protects against MPTP and 6-OHDA toxicity\n- **α-Synuclein effects**: May reduce aggregation or toxicity\n- **Anti-apoptotic signaling**: Through cAMP/PKA and PI3K pathways\n- **Anti-inflammatory**: Microglial suppression\n\n#### Clinical Trials\n\nβ2-agonists are being investigated for PD:\n\n- **Formoterol**: Long-acting β2-agonist in clinical trials\n- **Safety profile**: Generally well-tolerated\n- **CNS penetration**: A challenge for some compounds\n\n#### Autonomic Function\n\nβ2-AR contributes to autonomic regulation:\n\n- **Cardiac effects**: Modulates heart rate and contractility\n- **Blood pressure**: Influences vascular tone\n- **PD autonomic dysfunction**: Relevant to non-motor symptoms\n\n### Stroke and Cerebral Ischemia\n\nβ2-AR activation provides neuroprotection in stroke models[@park2020]:\n\n- **Infarct reduction**: Reduces cerebral infarction\n- **Anti-apoptotic**: Promotes neuronal survival\n- **Anti-inflammatory**: Reduces post-ischemic inflammation\n- **Angiogenesis**: May promote recovery\n\n### Mood Disorders\n\nThe β2-adrenergic system is relevant to depression:\n\n- **β2-AR downregulation**: Seen in depression\n- **Antidepressant effects**: Some antidepressants affect β2-AR signaling\n- **Therapeutic targeting**: β2-agonists have been explored\n\n## Expression Pattern\n\n### Central Nervous System\n\nIn the brain, β2-AR is expressed in:\n\n- **Hippocampus**: CA1-CA3 pyramidal cells, dentate gyrus granule cells\n- **Cerebral cortex**: Pyramidal neurons in all layers\n- **Cerebellum**: Purkinje cells and granule cells\n- **Amygdala**: Principal neurons\n- **Hypothalamus**: Regulatory neurons\n- **Basal forebrain**: Cholinergic projection neurons\n\n### Peripheral Tissues\n\nHighest peripheral expression:\n\n- **Lungs**: Bronchial smooth muscle (primary site)\n- **Heart**: Cardiac myocytes\n- **Liver**: Hepatocytes\n- **Skeletal muscle**: Muscle fibers\n- **Adipose tissue**: Brown and white adipocytes\n\n### Subcellular Localization\n\n- **Plasma membrane**: Primary location\n- **Endosomal compartments**: Internalized receptors\n- **Nucleus**: Some nuclear localization reported\n\n## Therapeutic Implications\n\n### Respiratory Diseases\n\nβ2-AR agonists are first-line treatments:\n\n| Drug | Type | Half-life | Clinical Use |\n|------|------|-----------|--------------|\n| Albuterol | SABA | 4-6 hours | Acute asthma |\n| Salmeterol | LABA | 12 hours | Maintenance asthma |\n| Formoterol | LABA | 12 hours | Asthma, COPD |\n| Indacaterol | LABA | 24 hours | COPD maintenance |\n\n### Neurodegeneration\n\nTherapeutic strategies include:\n\n1. **Brain-penetrant agonists**: Formoterol, arformoterol\n2. **β-arrestin biased ligands**: G protein-independent effects\n3. **Allosteric modulators**: Increase agonist potency\n4. **Combination approaches**: With cholinesterase inhibitors\n\n### Cardiovascular\n\nβ2-AR agonists have limited cardiac use:\n\n- **Acute decompensation**: Rarely used due to β1 effects\n- **Peripheral vasodilation**: Some β2-agonists cause hypotension\n- **Safety concerns**: Tremor and tachycardia\n\n## Animal Models\n\n### Genetic Models\n\n- **Adrb2 knockout mice**: Viable with respiratory and metabolic phenotypes\n- **Transgenic overexpression**: Tissue-specific models\n- **Humanized mice**: For drug testing\n\n### Phenotypes\n\n- **Respiratory**: Altered bronchial responsiveness\n- **Metabolic**: Changes in glycogen metabolism\n- **Cardiac**: Mild cardiac phenotypes\n- **Behavioral**: Altered stress responses\n\n### Disease Models\n\nTested in:\n- MPTP-induced parkinsonism\n- 6-OHDA lesion models\n- Transgenic AD models\n- Cerebral ischemia models\n\n## Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Epinephrine<br/>Norepinephrine\"] --> B[\"beta2-Adrenergic Receptor\"]\n    B --> C1[\"Gs Protein<br/>Coupling\"]\n    B --> C2[\"Gi Protein<br/>Coupling\"]\n    B --> C3[\"beta-Arrestin<br/>Pathway\"]\n\n    C1 --> D1[\"Adenylyl Cyclase<br/>up\"]\n    C1 --> D1\n    D1 --> E1[\"cAMP<br/>up\"]\n    E1 --> F1[\"PKA<br/>Activation\"]\n\n    F1 --> G1[\"CREB<br/>Phosphorylation\"]\n    F1 --> G2[\"Synaptic<br/>Plasticity\"]\n    F1 --> G3[\"Gene<br/>Transcription\"]\n    F1 --> G4[\"Anti-inflammatory<br/>Response\"]\n\n    C2 --> D2[\"Adenylyl Cyclase<br/>down\"]\n    D2 --> E2[\"cAMP<br/>down\"]\n    E2 --> F2[\"betagamma -> PI3K/Akt\"]\n\n    C3 --> D3[\"beta-Arrestin<br/>Scaffold\"]\n    D3 --> E3[\"ERK1/2<br/>Activation\"]\n    D3 --> F3[\"Akt<br/>Activation\"]\n\n    G1 --> H[\"Memory<br/>Consolidation\"]\n    G2 --> H\n    G3 --> I[\"Neuronal<br/>Survival\"]\n    G4 --> J[\"Neuroprotection\"]\n\n    style A fill:#0a1929,stroke:#333\n    style B fill:#0a1929,stroke:#333\n    style H fill:#0e2e10,stroke:#333\n    style I fill:#0e2e10,stroke:#333\n    style J fill:#0e2e10,stroke:#333\n```\n\n## Key Publications\n\n1. [Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation](https://pubmed.ncbi.nlm.nih.gov/24790844/)[@lefkowitz2014]\n2. [Moreau et al., 2018 - Formoterol rescues memory in AD models](https://pubmed.ncbi.nlm.nih.gov/29686311/)[@formoterol2018]\n3. [Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/30626698/)[@birmingham2019]\n4. [Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors](https://pubmed.ncbi.nlm.nih.gov/17291618/)[@galandrin2007]\n5. [Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization](https://pubmed.ncbi.nlm.nih.gov/27029639/)[@nichols2016]\n6. [Ibayashi et al., 2019 - Beta2-AR signaling in glial cells](https://pubmed.ncbi.nlm.nih.gov/31297657/)[@ibayashi2019]\n7. [Mittal et al., 2017 - ADRB2 polymorphisms and AD risk](https://pubmed.ncbi.nlm.nih.gov/28145406/)[@mittal2017]\n8. [Yan et al., 2019 - Beta2-agonists for PD disease modification](https://pubmed.ncbi.nlm.nih.gov/31154832/)[@yan2019]\n9. [Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/29488493/)[@wang2018]\n10. [Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production](https://pubmed.ncbi.nlm.nih.gov/28222568/)[@chen2017]\n11. [Yang et al., 2016 - Beta2-AR and neuroinflammation in AD](https://pubmed.ncbi.nlm.nih.gov/27117268/)[@yang2016]\n12. [Liu et al., 2018 - Beta2-AR in PD models](https://pubmed.ncbi.nlm.nih.gov/29604376/)[@liu2018]\n13. [Xiao et al., 2019 - Beta-adrenergic signaling in the heart](https://pubmed.ncbi.nlm.nih.gov/31788967/)[@xiao2019]\n14. [Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection](https://pubmed.ncbi.nlm.nih.gov/32877911/)[@park2020]\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)\n- [Beta-Adrenergic Receptors](/entities/beta-adrenergic-receptors)\n- [Memory Consolidation](/mechanisms/memory-consolidation)\n- [Neuroprotection](/therapeutics/neuroprotection)\n- [Norepinephrine](/entities/norepinephrine)\n- [Formoterol](/therapeutics/formoterol)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)\n- [UniProt: ADRB2](https://www.uniprot.org/uniprotkb/P07550)\n- [Ensembl: ADRB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252)\n- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)\n- [OMIM: ADRB2](https://omim.org/entry/109630)\n- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving ADRB2 Gene discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    GABRA1[\"GABRA1\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    CHAT[\"CHAT\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    CYP2D6[\"CYP2D6\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    APOE[\"APOE\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    HMGCR[\"HMGCR\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    OPRM1[\"OPRM1\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    SLC30A8[\"SLC30A8\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    COMT[\"COMT\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    NBEA[\"NBEA\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    HTR2C[\"HTR2C\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    ADRA2A[\"ADRA2A\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    BCHE[\"BCHE\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    SLC6A2[\"SLC6A2\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    SLC6A3[\"SLC6A3\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    MAOB[\"MAOB\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    style GABRA1 fill:#ce93d8,stroke:#333,color:#000\n    style ADRB2 fill:#ce93d8,stroke:#333,color:#000\n    style CHAT fill:#ce93d8,stroke:#333,color:#000\n    style CYP2D6 fill:#ce93d8,stroke:#333,color:#000\n    style APOE fill:#ce93d8,stroke:#333,color:#000\n    style HMGCR fill:#ce93d8,stroke:#333,color:#000\n    style OPRM1 fill:#ce93d8,stroke:#333,color:#000\n    style SLC30A8 fill:#ce93d8,stroke:#333,color:#000\n    style COMT fill:#ce93d8,stroke:#333,color:#000\n    style NBEA fill:#ce93d8,stroke:#333,color:#000\n    style HTR2C fill:#ce93d8,stroke:#333,color:#000\n    style ADRA2A fill:#ce93d8,stroke:#333,color:#000\n    style BCHE fill:#ce93d8,stroke:#333,color:#000\n    style SLC6A2 fill:#ce93d8,stroke:#333,color:#000\n    style SLC6A3 fill:#ce93d8,stroke:#333,color:#000\n    style MAOB fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "gene"
}

{
  "content_md": "# ADRB2 Gene\n\n<div class=\"infobox infobox-gene\">\n  <table>\n    <tr><th colspan=\"2\" style=\"background:#4477AA; color:white;\">ADRB2</th></tr>\n    <tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>\n    <tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>\n    <tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>\n    <tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>\n    <tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>\n    <tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>\n    <tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>\n    <tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>\n  </table>\n</div>\n\n## Overview\n\n**ADRB2** encodes the **β2-adrenergic receptor** (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].\n\nThe β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].\n\n## Molecular Biology and Structure\n\n### Gene Organization\n\nThe ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:\n\n- **TATA box**: Core promoter element\n- **CRE elements**: cAMP response elements for regulated expression\n- **AP-1 sites**: Responsive to growth factors and cytokines\n- **GRE**: Glucocorticoid response elements\n- **NF-κB elements**: Allows inflammatory regulation\n\nMultiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].\n\n### Protein Structure\n\nThe β2-adrenergic receptor has classical GPCR architecture:\n\n- **N-terminal extracellular domain** (1-39 aa): Contains two N-linked glycosylation sites\n- **Transmembrane domains** (TM1-TM7): Seven α-helices forming the ligand-binding pocket\n- **Extracellular loops** (ECL1-ECL3): ECL2 contains a conserved disulfide bond\n- **Intracellular loops** (ICL1-ICL3): ICL3 is the primary G protein coupling domain\n- **C-terminal tail** (342-413 aa): Contains serine/threonine phosphorylation sites\n\nThe ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:\n- Asp113 in TM3 (counterion for catecholamine amine)\n- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)\n- Phe282 (hydrophobic interactions with aromatic ring)\n\n### Splice Variants\n\nMultiple splice variants of ADRB2 have been described:\n- **β2-AR1**: Full-length 413 aa (predominant)\n- **β2-AR2**: Alternative C-terminus\n- **Truncated variants**: May have distinct signaling properties\n\n## Signaling Pathways\n\n### Primary Gs-cAMP Pathway\n\nUpon agonist binding:\n\n1. **Conformational change** activates Gs protein\n2. **Gαs-GTP** stimulates adenylyl cyclase\n3. **cAMP production** increases\n4. **PKA activation** leads to substrate phosphorylation\n5. **Physiological effects** on muscle relaxation, glycogenolysis, gene transcription\n\n### Alternative Gi/o Coupling\n\nIn some cell types, β2-AR couples to Gi/o:\n- **Inhibition of adenylyl cyclase** reduces cAMP\n- **βγ subunits** activate PI3K pathways\n- **Cell-type specificity** determines coupling preference\n\n### β-Arrestin Pathways\n\nβ2-AR signals through β-arrestins independently of G proteins:\n\n- **ERK1/2 activation** via β-arrestin scaffolds\n- **Akt activation** through similar mechanisms\n- **Receptor internalization** and recycling\n- **Biased signaling** potential for drug design\n\n### Receptor Dynamics\n\nβ2-AR exhibits unique properties:\n\n- **Constitutive activity**: Some basal signaling without agonist\n- **Inverse agonism**: Some ligands reduce baseline activity\n- **Allosteric modulators**: Bind at distinct sites\n- **Oligomerization**: May form heteromers with other GPCRs\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\n#### Memory Consolidation\n\nβ2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:\n\n- **Hippocampal LTP**: β2-AR activation enhances long-term potentiation\n- **Memory enhancement**: Agonists improve consolidation in multiple paradigms\n- **cAMP/PKA/CREB pathway**: Required for consolidation effects\n- **Time window**: Effects greatest during post-training period\n\nThe noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.\n\n#### Amyloid Pathology\n\nβ2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:\n\n- **APP processing**: cAMP can influence α-secretase activity\n- **Aβ production**: Effects are context-dependent\n- **Synaptic protection**: β2-AR activation protects against Aβ-induced synaptic dysfunction\n- **Neuronal survival**: Anti-apoptotic signaling through PI3K/Akt\n\n#### Neuroinflammation\n\nβ2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:\n\n- **Microglial inhibition**: β2-AR activation reduces pro-inflammatory cytokine release\n- **TNF-α suppression**: Reduces microglial activation\n- **IL-1β and IL-6**: Suppressed by β2-agonists\n- **Therapeutic potential**: Reduces neuroinflammation in AD models\n\n#### Genetic Associations\n\nSeveral studies link ADRB2 variants to AD risk[@mittal2017]:\n\n- **Functional polymorphisms** may alter receptor signaling\n- **Population-specific effects** observed in different cohorts\n- **Gene-environment interactions** with lifestyle factors\n\n### Parkinson's Disease\n\n#### Neuroprotection\n\nβ2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:\n\n- **Dopaminergic neuron survival**: Protects against MPTP and 6-OHDA toxicity\n- **α-Synuclein effects**: May reduce aggregation or toxicity\n- **Anti-apoptotic signaling**: Through cAMP/PKA and PI3K pathways\n- **Anti-inflammatory**: Microglial suppression\n\n#### Clinical Trials\n\nβ2-agonists are being investigated for PD:\n\n- **Formoterol**: Long-acting β2-agonist in clinical trials\n- **Safety profile**: Generally well-tolerated\n- **CNS penetration**: A challenge for some compounds\n\n#### Autonomic Function\n\nβ2-AR contributes to autonomic regulation:\n\n- **Cardiac effects**: Modulates heart rate and contractility\n- **Blood pressure**: Influences vascular tone\n- **PD autonomic dysfunction**: Relevant to non-motor symptoms\n\n### Stroke and Cerebral Ischemia\n\nβ2-AR activation provides neuroprotection in stroke models[@park2020]:\n\n- **Infarct reduction**: Reduces cerebral infarction\n- **Anti-apoptotic**: Promotes neuronal survival\n- **Anti-inflammatory**: Reduces post-ischemic inflammation\n- **Angiogenesis**: May promote recovery\n\n### Mood Disorders\n\nThe β2-adrenergic system is relevant to depression:\n\n- **β2-AR downregulation**: Seen in depression\n- **Antidepressant effects**: Some antidepressants affect β2-AR signaling\n- **Therapeutic targeting**: β2-agonists have been explored\n\n## Expression Pattern\n\n### Central Nervous System\n\nIn the brain, β2-AR is expressed in:\n\n- **Hippocampus**: CA1-CA3 pyramidal cells, dentate gyrus granule cells\n- **Cerebral cortex**: Pyramidal neurons in all layers\n- **Cerebellum**: Purkinje cells and granule cells\n- **Amygdala**: Principal neurons\n- **Hypothalamus**: Regulatory neurons\n- **Basal forebrain**: Cholinergic projection neurons\n\n### Peripheral Tissues\n\nHighest peripheral expression:\n\n- **Lungs**: Bronchial smooth muscle (primary site)\n- **Heart**: Cardiac myocytes\n- **Liver**: Hepatocytes\n- **Skeletal muscle**: Muscle fibers\n- **Adipose tissue**: Brown and white adipocytes\n\n### Subcellular Localization\n\n- **Plasma membrane**: Primary location\n- **Endosomal compartments**: Internalized receptors\n- **Nucleus**: Some nuclear localization reported\n\n## Therapeutic Implications\n\n### Respiratory Diseases\n\nβ2-AR agonists are first-line treatments:\n\n| Drug | Type | Half-life | Clinical Use |\n|------|------|-----------|--------------|\n| Albuterol | SABA | 4-6 hours | Acute asthma |\n| Salmeterol | LABA | 12 hours | Maintenance asthma |\n| Formoterol | LABA | 12 hours | Asthma, COPD |\n| Indacaterol | LABA | 24 hours | COPD maintenance |\n\n### Neurodegeneration\n\nTherapeutic strategies include:\n\n1. **Brain-penetrant agonists**: Formoterol, arformoterol\n2. **β-arrestin biased ligands**: G protein-independent effects\n3. **Allosteric modulators**: Increase agonist potency\n4. **Combination approaches**: With cholinesterase inhibitors\n\n### Cardiovascular\n\nβ2-AR agonists have limited cardiac use:\n\n- **Acute decompensation**: Rarely used due to β1 effects\n- **Peripheral vasodilation**: Some β2-agonists cause hypotension\n- **Safety concerns**: Tremor and tachycardia\n\n## Animal Models\n\n### Genetic Models\n\n- **Adrb2 knockout mice**: Viable with respiratory and metabolic phenotypes\n- **Transgenic overexpression**: Tissue-specific models\n- **Humanized mice**: For drug testing\n\n### Phenotypes\n\n- **Respiratory**: Altered bronchial responsiveness\n- **Metabolic**: Changes in glycogen metabolism\n- **Cardiac**: Mild cardiac phenotypes\n- **Behavioral**: Altered stress responses\n\n### Disease Models\n\nTested in:\n- MPTP-induced parkinsonism\n- 6-OHDA lesion models\n- Transgenic AD models\n- Cerebral ischemia models\n\n## Pathway Diagram\n\nflowchart TD\n    A[\"Epinephrine<br/>Norepinephrine\"] --> B[\"beta2-Adrenergic Receptor\"]\n    B --> C1[\"Gs Protein<br/>Coupling\"]\n    B --> C2[\"Gi Protein<br/>Coupling\"]\n    B --> C3[\"beta-Arrestin<br/>Pathway\"]\n\n    C1 --> D1[\"Adenylyl Cyclase<br/>up\"]\n    C1 --> D1\n    D1 --> E1[\"cAMP<br/>up\"]\n    E1 --> F1[\"PKA<br/>Activation\"]\n\n    F1 --> G1[\"CREB<br/>Phosphorylation\"]\n    F1 --> G2[\"Synaptic<br/>Plasticity\"]\n    F1 --> G3[\"Gene<br/>Transcription\"]\n    F1 --> G4[\"Anti-inflammatory<br/>Response\"]\n\n    C2 --> D2[\"Adenylyl Cyclase<br/>down\"]\n    D2 --> E2[\"cAMP<br/>down\"]\n    E2 --> F2[\"betagamma -> PI3K/Akt\"]\n\n    C3 --> D3[\"beta-Arrestin<br/>Scaffold\"]\n    D3 --> E3[\"ERK1/2<br/>Activation\"]\n    D3 --> F3[\"Akt<br/>Activation\"]\n\n    G1 --> H[\"Memory<br/>Consolidation\"]\n    G2 --> H\n    G3 --> I[\"Neuronal<br/>Survival\"]\n    G4 --> J[\"Neuroprotection\"]\n\n    style A fill:#0a1929,stroke:#333\n    style B fill:#0a1929,stroke:#333\n    style H fill:#0e2e10,stroke:#333\n    style I fill:#0e2e10,stroke:#333\n    style J fill:#0e2e10,stroke:#333\n\n## Key Publications\n\n1. [Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation](https://pubmed.ncbi.nlm.nih.gov/24790844/)[@lefkowitz2014]\n2. [Moreau et al., 2018 - Formoterol rescues memory in AD models](https://pubmed.ncbi.nlm.nih.gov/29686311/)[@formoterol2018]\n3. [Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/30626698/)[@birmingham2019]\n4. [Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors](https://pubmed.ncbi.nlm.nih.gov/17291618/)[@galandrin2007]\n5. [Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization](https://pubmed.ncbi.nlm.nih.gov/27029639/)[@nichols2016]\n6. [Ibayashi et al., 2019 - Beta2-AR signaling in glial cells](https://pubmed.ncbi.nlm.nih.gov/31297657/)[@ibayashi2019]\n7. [Mittal et al., 2017 - ADRB2 polymorphisms and AD risk](https://pubmed.ncbi.nlm.nih.gov/28145406/)[@mittal2017]\n8. [Yan et al., 2019 - Beta2-agonists for PD disease modification](https://pubmed.ncbi.nlm.nih.gov/31154832/)[@yan2019]\n9. [Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/29488493/)[@wang2018]\n10. [Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production](https://pubmed.ncbi.nlm.nih.gov/28222568/)[@chen2017]\n11. [Yang et al., 2016 - Beta2-AR and neuroinflammation in AD](https://pubmed.ncbi.nlm.nih.gov/27117268/)[@yang2016]\n12. [Liu et al., 2018 - Beta2-AR in PD models](https://pubmed.ncbi.nlm.nih.gov/29604376/)[@liu2018]\n13. [Xiao et al., 2019 - Beta-adrenergic signaling in the heart](https://pubmed.ncbi.nlm.nih.gov/31788967/)[@xiao2019]\n14. [Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection](https://pubmed.ncbi.nlm.nih.gov/32877911/)[@park2020]\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)\n- [Beta-Adrenergic Receptors](/entities/beta-adrenergic-receptors)\n- [Memory Consolidation](/mechanisms/memory-consolidation)\n- [Neuroprotection](/therapeutics/neuroprotection)\n- [Norepinephrine](/entities/norepinephrine)\n- [Formoterol](/therapeutics/formoterol)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)\n- [UniProt: ADRB2](https://www.uniprot.org/uniprotkb/P07550)\n- [Ensembl: ADRB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252)\n- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)\n- [OMIM: ADRB2](https://omim.org/entry/109630)\n- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving ADRB2 Gene discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    GABRA1[\"GABRA1\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    CHAT[\"CHAT\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    CYP2D6[\"CYP2D6\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    APOE[\"APOE\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    HMGCR[\"HMGCR\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    OPRM1[\"OPRM1\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    SLC30A8[\"SLC30A8\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    COMT[\"COMT\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    NBEA[\"NBEA\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    HTR2C[\"HTR2C\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    ADRA2A[\"ADRA2A\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    BCHE[\"BCHE\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    SLC6A2[\"SLC6A2\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    SLC6A3[\"SLC6A3\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    MAOB[\"MAOB\"] -->|\"associated with\"| ADRB2[\"ADRB2\"]\n    style GABRA1 fill:#ce93d8,stroke:#333,color:#000\n    style ADRB2 fill:#ce93d8,stroke:#333,color:#000\n    style CHAT fill:#ce93d8,stroke:#333,color:#000\n    style CYP2D6 fill:#ce93d8,stroke:#333,color:#000\n    style APOE fill:#ce93d8,stroke:#333,color:#000\n    style HMGCR fill:#ce93d8,stroke:#333,color:#000\n    style OPRM1 fill:#ce93d8,stroke:#333,color:#000\n    style SLC30A8 fill:#ce93d8,stroke:#333,color:#000\n    style COMT fill:#ce93d8,stroke:#333,color:#000\n    style NBEA fill:#ce93d8,stroke:#333,color:#000\n    style HTR2C fill:#ce93d8,stroke:#333,color:#000\n    style ADRA2A fill:#ce93d8,stroke:#333,color:#000\n    style BCHE fill:#ce93d8,stroke:#333,color:#000\n    style SLC6A2 fill:#ce93d8,stroke:#333,color:#000\n    style SLC6A3 fill:#ce93d8,stroke:#333,color:#000\n    style MAOB fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "gene"
}

{
  "content_md": "# ADRB2 Gene\n\n<div class=\"infobox infobox-gene\">\n  <table>\n    <tr><th colspan=\"2\" style=\"background:#4477AA; color:white;\">ADRB2</th></tr>\n    <tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>\n    <tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>\n    <tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>\n    <tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>\n    <tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>\n    <tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>\n    <tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>\n    <tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>\n  </table>\n</div>\n\n## Overview\n\n**ADRB2** encodes the **β2-adrenergic receptor** (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].\n\nThe β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].\n\n## Molecular Biology and Structure\n\n### Gene Organization\n\nThe ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:\n\n- **TATA box**: Core promoter element\n- **CRE elements**: cAMP response elements for regulated expression\n- **AP-1 sites**: Responsive to growth factors and cytokines\n- **GRE**: Glucocorticoid response elements\n- **NF-κB elements**: Allows inflammatory regulation\n\nMultiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].\n\n### Protein Structure\n\nThe β2-adrenergic receptor has classical GPCR architecture:\n\n- **N-terminal extracellular domain** (1-39 aa): Contains two N-linked glycosylation sites\n- **Transmembrane domains** (TM1-TM7): Seven α-helices forming the ligand-binding pocket\n- **Extracellular loops** (ECL1-ECL3): ECL2 contains a conserved disulfide bond\n- **Intracellular loops** (ICL1-ICL3): ICL3 is the primary G protein coupling domain\n- **C-terminal tail** (342-413 aa): Contains serine/threonine phosphorylation sites\n\nThe ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:\n- Asp113 in TM3 (counterion for catecholamine amine)\n- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)\n- Phe282 (hydrophobic interactions with aromatic ring)\n\n### Splice Variants\n\nMultiple splice variants of ADRB2 have been described:\n- **β2-AR1**: Full-length 413 aa (predominant)\n- **β2-AR2**: Alternative C-terminus\n- **Truncated variants**: May have distinct signaling properties\n\n## Signaling Pathways\n\n### Primary Gs-cAMP Pathway\n\nUpon agonist binding:\n\n1. **Conformational change** activates Gs protein\n2. **Gαs-GTP** stimulates adenylyl cyclase\n3. **cAMP production** increases\n4. **PKA activation** leads to substrate phosphorylation\n5. **Physiological effects** on muscle relaxation, glycogenolysis, gene transcription\n\n### Alternative Gi/o Coupling\n\nIn some cell types, β2-AR couples to Gi/o:\n- **Inhibition of adenylyl cyclase** reduces cAMP\n- **βγ subunits** activate PI3K pathways\n- **Cell-type specificity** determines coupling preference\n\n### β-Arrestin Pathways\n\nβ2-AR signals through β-arrestins independently of G proteins:\n\n- **ERK1/2 activation** via β-arrestin scaffolds\n- **Akt activation** through similar mechanisms\n- **Receptor internalization** and recycling\n- **Biased signaling** potential for drug design\n\n### Receptor Dynamics\n\nβ2-AR exhibits unique properties:\n\n- **Constitutive activity**: Some basal signaling without agonist\n- **Inverse agonism**: Some ligands reduce baseline activity\n- **Allosteric modulators**: Bind at distinct sites\n- **Oligomerization**: May form heteromers with other GPCRs\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\n#### Memory Consolidation\n\nβ2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:\n\n- **Hippocampal LTP**: β2-AR activation enhances long-term potentiation\n- **Memory enhancement**: Agonists improve consolidation in multiple paradigms\n- **cAMP/PKA/CREB pathway**: Required for consolidation effects\n- **Time window**: Effects greatest during post-training period\n\nThe noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.\n\n#### Amyloid Pathology\n\nβ2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:\n\n- **APP processing**: cAMP can influence α-secretase activity\n- **Aβ production**: Effects are context-dependent\n- **Synaptic protection**: β2-AR activation protects against Aβ-induced synaptic dysfunction\n- **Neuronal survival**: Anti-apoptotic signaling through PI3K/Akt\n\n#### Neuroinflammation\n\nβ2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:\n\n- **Microglial inhibition**: β2-AR activation reduces pro-inflammatory cytokine release\n- **TNF-α suppression**: Reduces microglial activation\n- **IL-1β and IL-6**: Suppressed by β2-agonists\n- **Therapeutic potential**: Reduces neuroinflammation in AD models\n\n#### Genetic Associations\n\nSeveral studies link ADRB2 variants to AD risk[@mittal2017]:\n\n- **Functional polymorphisms** may alter receptor signaling\n- **Population-specific effects** observed in different cohorts\n- **Gene-environment interactions** with lifestyle factors\n\n### Parkinson's Disease\n\n#### Neuroprotection\n\nβ2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:\n\n- **Dopaminergic neuron survival**: Protects against MPTP and 6-OHDA toxicity\n- **α-Synuclein effects**: May reduce aggregation or toxicity\n- **Anti-apoptotic signaling**: Through cAMP/PKA and PI3K pathways\n- **Anti-inflammatory**: Microglial suppression\n\n#### Clinical Trials\n\nβ2-agonists are being investigated for PD:\n\n- **Formoterol**: Long-acting β2-agonist in clinical trials\n- **Safety profile**: Generally well-tolerated\n- **CNS penetration**: A challenge for some compounds\n\n#### Autonomic Function\n\nβ2-AR contributes to autonomic regulation:\n\n- **Cardiac effects**: Modulates heart rate and contractility\n- **Blood pressure**: Influences vascular tone\n- **PD autonomic dysfunction**: Relevant to non-motor symptoms\n\n### Stroke and Cerebral Ischemia\n\nβ2-AR activation provides neuroprotection in stroke models[@park2020]:\n\n- **Infarct reduction**: Reduces cerebral infarction\n- **Anti-apoptotic**: Promotes neuronal survival\n- **Anti-inflammatory**: Reduces post-ischemic inflammation\n- **Angiogenesis**: May promote recovery\n\n### Mood Disorders\n\nThe β2-adrenergic system is relevant to depression:\n\n- **β2-AR downregulation**: Seen in depression\n- **Antidepressant effects**: Some antidepressants affect β2-AR signaling\n- **Therapeutic targeting**: β2-agonists have been explored\n\n## Expression Pattern\n\n### Central Nervous System\n\nIn the brain, β2-AR is expressed in:\n\n- **Hippocampus**: CA1-CA3 pyramidal cells, dentate gyrus granule cells\n- **Cerebral cortex**: Pyramidal neurons in all layers\n- **Cerebellum**: Purkinje cells and granule cells\n- **Amygdala**: Principal neurons\n- **Hypothalamus**: Regulatory neurons\n- **Basal forebrain**: Cholinergic projection neurons\n\n### Peripheral Tissues\n\nHighest peripheral expression:\n\n- **Lungs**: Bronchial smooth muscle (primary site)\n- **Heart**: Cardiac myocytes\n- **Liver**: Hepatocytes\n- **Skeletal muscle**: Muscle fibers\n- **Adipose tissue**: Brown and white adipocytes\n\n### Subcellular Localization\n\n- **Plasma membrane**: Primary location\n- **Endosomal compartments**: Internalized receptors\n- **Nucleus**: Some nuclear localization reported\n\n## Therapeutic Implications\n\n### Respiratory Diseases\n\nβ2-AR agonists are first-line treatments:\n\n| Drug | Type | Half-life | Clinical Use |\n|------|------|-----------|--------------|\n| Albuterol | SABA | 4-6 hours | Acute asthma |\n| Salmeterol | LABA | 12 hours | Maintenance asthma |\n| Formoterol | LABA | 12 hours | Asthma, COPD |\n| Indacaterol | LABA | 24 hours | COPD maintenance |\n\n### Neurodegeneration\n\nTherapeutic strategies include:\n\n1. **Brain-penetrant agonists**: Formoterol, arformoterol\n2. **β-arrestin biased ligands**: G protein-independent effects\n3. **Allosteric modulators**: Increase agonist potency\n4. **Combination approaches**: With cholinesterase inhibitors\n\n### Cardiovascular\n\nβ2-AR agonists have limited cardiac use:\n\n- **Acute decompensation**: Rarely used due to β1 effects\n- **Peripheral vasodilation**: Some β2-agonists cause hypotension\n- **Safety concerns**: Tremor and tachycardia\n\n## Animal Models\n\n### Genetic Models\n\n- **Adrb2 knockout mice**: Viable with respiratory and metabolic phenotypes\n- **Transgenic overexpression**: Tissue-specific models\n- **Humanized mice**: For drug testing\n\n### Phenotypes\n\n- **Respiratory**: Altered bronchial responsiveness\n- **Metabolic**: Changes in glycogen metabolism\n- **Cardiac**: Mild cardiac phenotypes\n- **Behavioral**: Altered stress responses\n\n### Disease Models\n\nTested in:\n- MPTP-induced parkinsonism\n- 6-OHDA lesion models\n- Transgenic AD models\n- Cerebral ischemia models\n\n## Pathway Diagram\n\nflowchart TD\n    A[\"Epinephrine<br/>Norepinephrine\"] --> B[\"beta2-Adrenergic Receptor\"]\n    B --> C1[\"Gs Protein<br/>Coupling\"]\n    B --> C2[\"Gi Protein<br/>Coupling\"]\n    B --> C3[\"beta-Arrestin<br/>Pathway\"]\n\n    C1 --> D1[\"Adenylyl Cyclase<br/>up\"]\n    C1 --> D1\n    D1 --> E1[\"cAMP<br/>up\"]\n    E1 --> F1[\"PKA<br/>Activation\"]\n\n    F1 --> G1[\"CREB<br/>Phosphorylation\"]\n    F1 --> G2[\"Synaptic<br/>Plasticity\"]\n    F1 --> G3[\"Gene<br/>Transcription\"]\n    F1 --> G4[\"Anti-inflammatory<br/>Response\"]\n\n    C2 --> D2[\"Adenylyl Cyclase<br/>down\"]\n    D2 --> E2[\"cAMP<br/>down\"]\n    E2 --> F2[\"betagamma -> PI3K/Akt\"]\n\n    C3 --> D3[\"beta-Arrestin<br/>Scaffold\"]\n    D3 --> E3[\"ERK1/2<br/>Activation\"]\n    D3 --> F3[\"Akt<br/>Activation\"]\n\n    G1 --> H[\"Memory<br/>Consolidation\"]\n    G2 --> H\n    G3 --> I[\"Neuronal<br/>Survival\"]\n    G4 --> J[\"Neuroprotection\"]\n\n    style A fill:#0a1929,stroke:#333\n    style B fill:#0a1929,stroke:#333\n    style H fill:#0e2e10,stroke:#333\n    style I fill:#0e2e10,stroke:#333\n    style J fill:#0e2e10,stroke:#333\n\n## Key Publications\n\n1. [Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation](https://pubmed.ncbi.nlm.nih.gov/24790844/)[@lefkowitz2014]\n2. [Moreau et al., 2018 - Formoterol rescues memory in AD models](https://pubmed.ncbi.nlm.nih.gov/29686311/)[@formoterol2018]\n3. [Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/30626698/)[@birmingham2019]\n4. [Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors](https://pubmed.ncbi.nlm.nih.gov/17291618/)[@galandrin2007]\n5. [Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization](https://pubmed.ncbi.nlm.nih.gov/27029639/)[@nichols2016]\n6. [Ibayashi et al., 2019 - Beta2-AR signaling in glial cells](https://pubmed.ncbi.nlm.nih.gov/31297657/)[@ibayashi2019]\n7. [Mittal et al., 2017 - ADRB2 polymorphisms and AD risk](https://pubmed.ncbi.nlm.nih.gov/28145406/)[@mittal2017]\n8. [Yan et al., 2019 - Beta2-agonists for PD disease modification](https://pubmed.ncbi.nlm.nih.gov/31154832/)[@yan2019]\n9. [Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/29488493/)[@wang2018]\n10. [Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production](https://pubmed.ncbi.nlm.nih.gov/28222568/)[@chen2017]\n11. [Yang et al., 2016 - Beta2-AR and neuroinflammation in AD](https://pubmed.ncbi.nlm.nih.gov/27117268/)[@yang2016]\n12. [Liu et al., 2018 - Beta2-AR in PD models](https://pubmed.ncbi.nlm.nih.gov/29604376/)[@liu2018]\n13. [Xiao et al., 2019 - Beta-adrenergic signaling in the heart](https://pubmed.ncbi.nlm.nih.gov/31788967/)[@xiao2019]\n14. [Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection](https://pubmed.ncbi.nlm.nih.gov/32877911/)[@park2020]\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)\n- [Beta-Adrenergic Receptors](/entities/beta-adrenergic-receptors)\n- [Memory Consolidation](/mechanisms/memory-consolidation)\n- [Neuroprotection](/therapeutics/neuroprotection)\n- [Norepinephrine](/entities/norepinephrine)\n- [Formoterol](/therapeutics/formoterol)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)\n- [UniProt: ADRB2](https://www.uniprot.org/uniprotkb/P07550)\n- [Ensembl: ADRB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252)\n- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)\n- [OMIM: ADRB2](https://omim.org/entry/109630)\n- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)\n",
  "entity_type": "gene"
}

{
  "content_md": "# ADRB2 Gene\n\n<div class=\"infobox infobox-gene\">\n  <table>\n    <tr><th colspan=\"2\" style=\"background:#4477AA; color:white;\">ADRB2</th></tr>\n    <tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>\n    <tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>\n    <tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>\n    <tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>\n    <tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>\n    <tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>\n    <tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>\n    <tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>\n  </table>\n</div>\n\n## Overview\n\n**ADRB2** encodes the **β2-adrenergic receptor** (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].\n\nThe β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].\n\n## Molecular Biology and Structure\n\n### Gene Organization\n\nThe ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:\n\n- **TATA box**: Core promoter element\n- **CRE elements**: cAMP response elements for regulated expression\n- **AP-1 sites**: Responsive to growth factors and cytokines\n- **GRE**: Glucocorticoid response elements\n- **NF-κB elements**: Allows inflammatory regulation\n\nMultiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].\n\n### Protein Structure\n\nThe β2-adrenergic receptor has classical GPCR architecture:\n\n- **N-terminal extracellular domain** (1-39 aa): Contains two N-linked glycosylation sites\n- **Transmembrane domains** (TM1-TM7): Seven α-helices forming the ligand-binding pocket\n- **Extracellular loops** (ECL1-ECL3): ECL2 contains a conserved disulfide bond\n- **Intracellular loops** (ICL1-ICL3): ICL3 is the primary G protein coupling domain\n- **C-terminal tail** (342-413 aa): Contains serine/threonine phosphorylation sites\n\nThe ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:\n- Asp113 in TM3 (counterion for catecholamine amine)\n- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)\n- Phe282 (hydrophobic interactions with aromatic ring)\n\n### Splice Variants\n\nMultiple splice variants of ADRB2 have been described:\n- **β2-AR1**: Full-length 413 aa (predominant)\n- **β2-AR2**: Alternative C-terminus\n- **Truncated variants**: May have distinct signaling properties\n\n## Signaling Pathways\n\n### Primary Gs-cAMP Pathway\n\nUpon agonist binding:\n\n1. **Conformational change** activates Gs protein\n2. **Gαs-GTP** stimulates adenylyl cyclase\n3. **cAMP production** increases\n4. **PKA activation** leads to substrate phosphorylation\n5. **Physiological effects** on muscle relaxation, glycogenolysis, gene transcription\n\n### Alternative Gi/o Coupling\n\nIn some cell types, β2-AR couples to Gi/o:\n- **Inhibition of adenylyl cyclase** reduces cAMP\n- **βγ subunits** activate PI3K pathways\n- **Cell-type specificity** determines coupling preference\n\n### β-Arrestin Pathways\n\nβ2-AR signals through β-arrestins independently of G proteins:\n\n- **ERK1/2 activation** via β-arrestin scaffolds\n- **Akt activation** through similar mechanisms\n- **Receptor internalization** and recycling\n- **Biased signaling** potential for drug design\n\n### Receptor Dynamics\n\nβ2-AR exhibits unique properties:\n\n- **Constitutive activity**: Some basal signaling without agonist\n- **Inverse agonism**: Some ligands reduce baseline activity\n- **Allosteric modulators**: Bind at distinct sites\n- **Oligomerization**: May form heteromers with other GPCRs\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\n#### Memory Consolidation\n\nβ2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:\n\n- **Hippocampal LTP**: β2-AR activation enhances long-term potentiation\n- **Memory enhancement**: Agonists improve consolidation in multiple paradigms\n- **cAMP/PKA/CREB pathway**: Required for consolidation effects\n- **Time window**: Effects greatest during post-training period\n\nThe noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.\n\n#### Amyloid Pathology\n\nβ2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:\n\n- **APP processing**: cAMP can influence α-secretase activity\n- **Aβ production**: Effects are context-dependent\n- **Synaptic protection**: β2-AR activation protects against Aβ-induced synaptic dysfunction\n- **Neuronal survival**: Anti-apoptotic signaling through PI3K/Akt\n\n#### Neuroinflammation\n\nβ2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:\n\n- **Microglial inhibition**: β2-AR activation reduces pro-inflammatory cytokine release\n- **TNF-α suppression**: Reduces microglial activation\n- **IL-1β and IL-6**: Suppressed by β2-agonists\n- **Therapeutic potential**: Reduces neuroinflammation in AD models\n\n#### Genetic Associations\n\nSeveral studies link ADRB2 variants to AD risk[@mittal2017]:\n\n- **Functional polymorphisms** may alter receptor signaling\n- **Population-specific effects** observed in different cohorts\n- **Gene-environment interactions** with lifestyle factors\n\n### Parkinson's Disease\n\n#### Neuroprotection\n\nβ2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:\n\n- **Dopaminergic neuron survival**: Protects against MPTP and 6-OHDA toxicity\n- **α-Synuclein effects**: May reduce aggregation or toxicity\n- **Anti-apoptotic signaling**: Through cAMP/PKA and PI3K pathways\n- **Anti-inflammatory**: Microglial suppression\n\n#### Clinical Trials\n\nβ2-agonists are being investigated for PD:\n\n- **Formoterol**: Long-acting β2-agonist in clinical trials\n- **Safety profile**: Generally well-tolerated\n- **CNS penetration**: A challenge for some compounds\n\n#### Autonomic Function\n\nβ2-AR contributes to autonomic regulation:\n\n- **Cardiac effects**: Modulates heart rate and contractility\n- **Blood pressure**: Influences vascular tone\n- **PD autonomic dysfunction**: Relevant to non-motor symptoms\n\n### Stroke and Cerebral Ischemia\n\nβ2-AR activation provides neuroprotection in stroke models[@park2020]:\n\n- **Infarct reduction**: Reduces cerebral infarction\n- **Anti-apoptotic**: Promotes neuronal survival\n- **Anti-inflammatory**: Reduces post-ischemic inflammation\n- **Angiogenesis**: May promote recovery\n\n### Mood Disorders\n\nThe β2-adrenergic system is relevant to depression:\n\n- **β2-AR downregulation**: Seen in depression\n- **Antidepressant effects**: Some antidepressants affect β2-AR signaling\n- **Therapeutic targeting**: β2-agonists have been explored\n\n## Expression Pattern\n\n### Central Nervous System\n\nIn the brain, β2-AR is expressed in:\n\n- **Hippocampus**: CA1-CA3 pyramidal cells, dentate gyrus granule cells\n- **Cerebral cortex**: Pyramidal neurons in all layers\n- **Cerebellum**: Purkinje cells and granule cells\n- **Amygdala**: Principal neurons\n- **Hypothalamus**: Regulatory neurons\n- **Basal forebrain**: Cholinergic projection neurons\n\n### Peripheral Tissues\n\nHighest peripheral expression:\n\n- **Lungs**: Bronchial smooth muscle (primary site)\n- **Heart**: Cardiac myocytes\n- **Liver**: Hepatocytes\n- **Skeletal muscle**: Muscle fibers\n- **Adipose tissue**: Brown and white adipocytes\n\n### Subcellular Localization\n\n- **Plasma membrane**: Primary location\n- **Endosomal compartments**: Internalized receptors\n- **Nucleus**: Some nuclear localization reported\n\n## Therapeutic Implications\n\n### Respiratory Diseases\n\nβ2-AR agonists are first-line treatments:\n\n| Drug | Type | Half-life | Clinical Use |\n|------|------|-----------|--------------|\n| Albuterol | SABA | 4-6 hours | Acute asthma |\n| Salmeterol | LABA | 12 hours | Maintenance asthma |\n| Formoterol | LABA | 12 hours | Asthma, COPD |\n| Indacaterol | LABA | 24 hours | COPD maintenance |\n\n### Neurodegeneration\n\nTherapeutic strategies include:\n\n1. **Brain-penetrant agonists**: Formoterol, arformoterol\n2. **β-arrestin biased ligands**: G protein-independent effects\n3. **Allosteric modulators**: Increase agonist potency\n4. **Combination approaches**: With cholinesterase inhibitors\n\n### Cardiovascular\n\nβ2-AR agonists have limited cardiac use:\n\n- **Acute decompensation**: Rarely used due to β1 effects\n- **Peripheral vasodilation**: Some β2-agonists cause hypotension\n- **Safety concerns**: Tremor and tachycardia\n\n## Animal Models\n\n### Genetic Models\n\n- **Adrb2 knockout mice**: Viable with respiratory and metabolic phenotypes\n- **Transgenic overexpression**: Tissue-specific models\n- **Humanized mice**: For drug testing\n\n### Phenotypes\n\n- **Respiratory**: Altered bronchial responsiveness\n- **Metabolic**: Changes in glycogen metabolism\n- **Cardiac**: Mild cardiac phenotypes\n- **Behavioral**: Altered stress responses\n\n### Disease Models\n\nTested in:\n- MPTP-induced parkinsonism\n- 6-OHDA lesion models\n- Transgenic AD models\n- Cerebral ischemia models\n\n## Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Epinephrine<br/>Norepinephrine\"] --> B[\"beta2-Adrenergic Receptor\"]\n    B --> C1[\"Gs Protein<br/>Coupling\"]\n    B --> C2[\"Gi Protein<br/>Coupling\"]\n    B --> C3[\"beta-Arrestin<br/>Pathway\"]\n\n    C1 --> D1[\"Adenylyl Cyclase<br/>up\"]\n    C1 --> D1\n    D1 --> E1[\"cAMP<br/>up\"]\n    E1 --> F1[\"PKA<br/>Activation\"]\n\n    F1 --> G1[\"CREB<br/>Phosphorylation\"]\n    F1 --> G2[\"Synaptic<br/>Plasticity\"]\n    F1 --> G3[\"Gene<br/>Transcription\"]\n    F1 --> G4[\"Anti-inflammatory<br/>Response\"]\n\n    C2 --> D2[\"Adenylyl Cyclase<br/>down\"]\n    D2 --> E2[\"cAMP<br/>down\"]\n    E2 --> F2[\"betagamma -> PI3K/Akt\"]\n\n    C3 --> D3[\"beta-Arrestin<br/>Scaffold\"]\n    D3 --> E3[\"ERK1/2<br/>Activation\"]\n    D3 --> F3[\"Akt<br/>Activation\"]\n\n    G1 --> H[\"Memory<br/>Consolidation\"]\n    G2 --> H\n    G3 --> I[\"Neuronal<br/>Survival\"]\n    G4 --> J[\"Neuroprotection\"]\n\n    style A fill:#0a1929,stroke:#333\n    style B fill:#0a1929,stroke:#333\n    style H fill:#0e2e10,stroke:#333\n    style I fill:#0e2e10,stroke:#333\n    style J fill:#0e2e10,stroke:#333\n```\n\n## Key Publications\n\n1. [Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation](https://pubmed.ncbi.nlm.nih.gov/24790844/)[@lefkowitz2014]\n2. [Moreau et al., 2018 - Formoterol rescues memory in AD models](https://pubmed.ncbi.nlm.nih.gov/29686311/)[@formoterol2018]\n3. [Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/30626698/)[@birmingham2019]\n4. [Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors](https://pubmed.ncbi.nlm.nih.gov/17291618/)[@galandrin2007]\n5. [Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization](https://pubmed.ncbi.nlm.nih.gov/27029639/)[@nichols2016]\n6. [Ibayashi et al., 2019 - Beta2-AR signaling in glial cells](https://pubmed.ncbi.nlm.nih.gov/31297657/)[@ibayashi2019]\n7. [Mittal et al., 2017 - ADRB2 polymorphisms and AD risk](https://pubmed.ncbi.nlm.nih.gov/28145406/)[@mittal2017]\n8. [Yan et al., 2019 - Beta2-agonists for PD disease modification](https://pubmed.ncbi.nlm.nih.gov/31154832/)[@yan2019]\n9. [Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/29488493/)[@wang2018]\n10. [Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production](https://pubmed.ncbi.nlm.nih.gov/28222568/)[@chen2017]\n11. [Yang et al., 2016 - Beta2-AR and neuroinflammation in AD](https://pubmed.ncbi.nlm.nih.gov/27117268/)[@yang2016]\n12. [Liu et al., 2018 - Beta2-AR in PD models](https://pubmed.ncbi.nlm.nih.gov/29604376/)[@liu2018]\n13. [Xiao et al., 2019 - Beta-adrenergic signaling in the heart](https://pubmed.ncbi.nlm.nih.gov/31788967/)[@xiao2019]\n14. [Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection](https://pubmed.ncbi.nlm.nih.gov/32877911/)[@park2020]\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)\n- [Beta-Adrenergic Receptors](/entities/beta-adrenergic-receptors)\n- [Memory Consolidation](/mechanisms/memory-consolidation)\n- [Neuroprotection](/therapeutics/neuroprotection)\n- [Norepinephrine](/entities/norepinephrine)\n- [Formoterol](/therapeutics/formoterol)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)\n- [UniProt: ADRB2](https://www.uniprot.org/uniprotkb/P07550)\n- [Ensembl: ADRB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252)\n- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)\n- [OMIM: ADRB2](https://omim.org/entry/109630)\n- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)\n",
  "entity_type": "gene"
}

{
  "content_md": "<div class=\"infobox infobox-gene\">\n  <table>\n    <tr><th colspan=\"2\" style=\"background:#4477AA; color:white;\">ADRB2</th></tr>\n    <tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>\n    <tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>\n    <tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>\n    <tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>\n    <tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>\n    <tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>\n    <tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>\n    <tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>\n  </table>\n</div>\n\n## Overview\n\n**ADRB2** encodes the **β2-adrenergic receptor** (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].\n\nThe β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].\n\n## Molecular Biology and Structure\n\n### Gene Organization\n\nThe ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:\n\n- **TATA box**: Core promoter element\n- **CRE elements**: cAMP response elements for regulated expression\n- **AP-1 sites**: Responsive to growth factors and cytokines\n- **GRE**: Glucocorticoid response elements\n- **NF-κB elements**: Allows inflammatory regulation\n\nMultiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].\n\n### Protein Structure\n\nThe β2-adrenergic receptor has classical GPCR architecture:\n\n- **N-terminal extracellular domain** (1-39 aa): Contains two N-linked glycosylation sites\n- **Transmembrane domains** (TM1-TM7): Seven α-helices forming the ligand-binding pocket\n- **Extracellular loops** (ECL1-ECL3): ECL2 contains a conserved disulfide bond\n- **Intracellular loops** (ICL1-ICL3): ICL3 is the primary G protein coupling domain\n- **C-terminal tail** (342-413 aa): Contains serine/threonine phosphorylation sites\n\nThe ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:\n- Asp113 in TM3 (counterion for catecholamine amine)\n- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)\n- Phe282 (hydrophobic interactions with aromatic ring)\n\n### Splice Variants\n\nMultiple splice variants of ADRB2 have been described:\n- **β2-AR1**: Full-length 413 aa (predominant)\n- **β2-AR2**: Alternative C-terminus\n- **Truncated variants**: May have distinct signaling properties\n\n## Signaling Pathways\n\n### Primary Gs-cAMP Pathway\n\nUpon agonist binding:\n\n1. **Conformational change** activates Gs protein\n2. **Gαs-GTP** stimulates adenylyl cyclase\n3. **cAMP production** increases\n4. **PKA activation** leads to substrate phosphorylation\n5. **Physiological effects** on muscle relaxation, glycogenolysis, gene transcription\n\n### Alternative Gi/o Coupling\n\nIn some cell types, β2-AR couples to Gi/o:\n- **Inhibition of adenylyl cyclase** reduces cAMP\n- **βγ subunits** activate PI3K pathways\n- **Cell-type specificity** determines coupling preference\n\n### β-Arrestin Pathways\n\nβ2-AR signals through β-arrestins independently of G proteins:\n\n- **ERK1/2 activation** via β-arrestin scaffolds\n- **Akt activation** through similar mechanisms\n- **Receptor internalization** and recycling\n- **Biased signaling** potential for drug design\n\n### Receptor Dynamics\n\nβ2-AR exhibits unique properties:\n\n- **Constitutive activity**: Some basal signaling without agonist\n- **Inverse agonism**: Some ligands reduce baseline activity\n- **Allosteric modulators**: Bind at distinct sites\n- **Oligomerization**: May form heteromers with other GPCRs\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\n#### Memory Consolidation\n\nβ2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:\n\n- **Hippocampal LTP**: β2-AR activation enhances long-term potentiation\n- **Memory enhancement**: Agonists improve consolidation in multiple paradigms\n- **cAMP/PKA/CREB pathway**: Required for consolidation effects\n- **Time window**: Effects greatest during post-training period\n\nThe noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.\n\n#### Amyloid Pathology\n\nβ2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:\n\n- **APP processing**: cAMP can influence α-secretase activity\n- **Aβ production**: Effects are context-dependent\n- **Synaptic protection**: β2-AR activation protects against Aβ-induced synaptic dysfunction\n- **Neuronal survival**: Anti-apoptotic signaling through PI3K/Akt\n\n#### Neuroinflammation\n\nβ2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:\n\n- **Microglial inhibition**: β2-AR activation reduces pro-inflammatory cytokine release\n- **TNF-α suppression**: Reduces microglial activation\n- **IL-1β and IL-6**: Suppressed by β2-agonists\n- **Therapeutic potential**: Reduces neuroinflammation in AD models\n\n#### Genetic Associations\n\nSeveral studies link ADRB2 variants to AD risk[@mittal2017]:\n\n- **Functional polymorphisms** may alter receptor signaling\n- **Population-specific effects** observed in different cohorts\n- **Gene-environment interactions** with lifestyle factors\n\n### Parkinson's Disease\n\n#### Neuroprotection\n\nβ2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:\n\n- **Dopaminergic neuron survival**: Protects against MPTP and 6-OHDA toxicity\n- **α-Synuclein effects**: May reduce aggregation or toxicity\n- **Anti-apoptotic signaling**: Through cAMP/PKA and PI3K pathways\n- **Anti-inflammatory**: Microglial suppression\n\n#### Clinical Trials\n\nβ2-agonists are being investigated for PD:\n\n- **Formoterol**: Long-acting β2-agonist in clinical trials\n- **Safety profile**: Generally well-tolerated\n- **CNS penetration**: A challenge for some compounds\n\n#### Autonomic Function\n\nβ2-AR contributes to autonomic regulation:\n\n- **Cardiac effects**: Modulates heart rate and contractility\n- **Blood pressure**: Influences vascular tone\n- **PD autonomic dysfunction**: Relevant to non-motor symptoms\n\n### Stroke and Cerebral Ischemia\n\nβ2-AR activation provides neuroprotection in stroke models[@park2020]:\n\n- **Infarct reduction**: Reduces cerebral infarction\n- **Anti-apoptotic**: Promotes neuronal survival\n- **Anti-inflammatory**: Reduces post-ischemic inflammation\n- **Angiogenesis**: May promote recovery\n\n### Mood Disorders\n\nThe β2-adrenergic system is relevant to depression:\n\n- **β2-AR downregulation**: Seen in depression\n- **Antidepressant effects**: Some antidepressants affect β2-AR signaling\n- **Therapeutic targeting**: β2-agonists have been explored\n\n## Expression Pattern\n\n### Central Nervous System\n\nIn the brain, β2-AR is expressed in:\n\n- **Hippocampus**: CA1-CA3 pyramidal cells, dentate gyrus granule cells\n- **Cerebral cortex**: Pyramidal neurons in all layers\n- **Cerebellum**: Purkinje cells and granule cells\n- **Amygdala**: Principal neurons\n- **Hypothalamus**: Regulatory neurons\n- **Basal forebrain**: Cholinergic projection neurons\n\n### Peripheral Tissues\n\nHighest peripheral expression:\n\n- **Lungs**: Bronchial smooth muscle (primary site)\n- **Heart**: Cardiac myocytes\n- **Liver**: Hepatocytes\n- **Skeletal muscle**: Muscle fibers\n- **Adipose tissue**: Brown and white adipocytes\n\n### Subcellular Localization\n\n- **Plasma membrane**: Primary location\n- **Endosomal compartments**: Internalized receptors\n- **Nucleus**: Some nuclear localization reported\n\n## Therapeutic Implications\n\n### Respiratory Diseases\n\nβ2-AR agonists are first-line treatments:\n\n| Drug | Type | Half-life | Clinical Use |\n|------|------|-----------|--------------|\n| Albuterol | SABA | 4-6 hours | Acute asthma |\n| Salmeterol | LABA | 12 hours | Maintenance asthma |\n| Formoterol | LABA | 12 hours | Asthma, COPD |\n| Indacaterol | LABA | 24 hours | COPD maintenance |\n\n### Neurodegeneration\n\nTherapeutic strategies include:\n\n1. **Brain-penetrant agonists**: Formoterol, arformoterol\n2. **β-arrestin biased ligands**: G protein-independent effects\n3. **Allosteric modulators**: Increase agonist potency\n4. **Combination approaches**: With cholinesterase inhibitors\n\n### Cardiovascular\n\nβ2-AR agonists have limited cardiac use:\n\n- **Acute decompensation**: Rarely used due to β1 effects\n- **Peripheral vasodilation**: Some β2-agonists cause hypotension\n- **Safety concerns**: Tremor and tachycardia\n\n## Animal Models\n\n### Genetic Models\n\n- **Adrb2 knockout mice**: Viable with respiratory and metabolic phenotypes\n- **Transgenic overexpression**: Tissue-specific models\n- **Humanized mice**: For drug testing\n\n### Phenotypes\n\n- **Respiratory**: Altered bronchial responsiveness\n- **Metabolic**: Changes in glycogen metabolism\n- **Cardiac**: Mild cardiac phenotypes\n- **Behavioral**: Altered stress responses\n\n### Disease Models\n\nTested in:\n- MPTP-induced parkinsonism\n- 6-OHDA lesion models\n- Transgenic AD models\n- Cerebral ischemia models\n\n## Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Epinephrine<br/>Norepinephrine\"] --> B[\"beta2-Adrenergic Receptor\"]\n    B --> C1[\"Gs Protein<br/>Coupling\"]\n    B --> C2[\"Gi Protein<br/>Coupling\"]\n    B --> C3[\"beta-Arrestin<br/>Pathway\"]\n\n    C1 --> D1[\"Adenylyl Cyclase<br/>up\"]\n    C1 --> D1\n    D1 --> E1[\"cAMP<br/>up\"]\n    E1 --> F1[\"PKA<br/>Activation\"]\n\n    F1 --> G1[\"CREB<br/>Phosphorylation\"]\n    F1 --> G2[\"Synaptic<br/>Plasticity\"]\n    F1 --> G3[\"Gene<br/>Transcription\"]\n    F1 --> G4[\"Anti-inflammatory<br/>Response\"]\n\n    C2 --> D2[\"Adenylyl Cyclase<br/>down\"]\n    D2 --> E2[\"cAMP<br/>down\"]\n    E2 --> F2[\"betagamma -> PI3K/Akt\"]\n\n    C3 --> D3[\"beta-Arrestin<br/>Scaffold\"]\n    D3 --> E3[\"ERK1/2<br/>Activation\"]\n    D3 --> F3[\"Akt<br/>Activation\"]\n\n    G1 --> H[\"Memory<br/>Consolidation\"]\n    G2 --> H\n    G3 --> I[\"Neuronal<br/>Survival\"]\n    G4 --> J[\"Neuroprotection\"]\n\n    style A fill:#0a1929,stroke:#333\n    style B fill:#0a1929,stroke:#333\n    style H fill:#0e2e10,stroke:#333\n    style I fill:#0e2e10,stroke:#333\n    style J fill:#0e2e10,stroke:#333\n```\n\n## Key Publications\n\n1. [Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation](https://pubmed.ncbi.nlm.nih.gov/24790844/)[@lefkowitz2014]\n2. [Moreau et al., 2018 - Formoterol rescues memory in AD models](https://pubmed.ncbi.nlm.nih.gov/29686311/)[@formoterol2018]\n3. [Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/30626698/)[@birmingham2019]\n4. [Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors](https://pubmed.ncbi.nlm.nih.gov/17291618/)[@galandrin2007]\n5. [Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization](https://pubmed.ncbi.nlm.nih.gov/27029639/)[@nichols2016]\n6. [Ibayashi et al., 2019 - Beta2-AR signaling in glial cells](https://pubmed.ncbi.nlm.nih.gov/31297657/)[@ibayashi2019]\n7. [Mittal et al., 2017 - ADRB2 polymorphisms and AD risk](https://pubmed.ncbi.nlm.nih.gov/28145406/)[@mittal2017]\n8. [Yan et al., 2019 - Beta2-agonists for PD disease modification](https://pubmed.ncbi.nlm.nih.gov/31154832/)[@yan2019]\n9. [Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/29488493/)[@wang2018]\n10. [Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production](https://pubmed.ncbi.nlm.nih.gov/28222568/)[@chen2017]\n11. [Yang et al., 2016 - Beta2-AR and neuroinflammation in AD](https://pubmed.ncbi.nlm.nih.gov/27117268/)[@yang2016]\n12. [Liu et al., 2018 - Beta2-AR in PD models](https://pubmed.ncbi.nlm.nih.gov/29604376/)[@liu2018]\n13. [Xiao et al., 2019 - Beta-adrenergic signaling in the heart](https://pubmed.ncbi.nlm.nih.gov/31788967/)[@xiao2019]\n14. [Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection](https://pubmed.ncbi.nlm.nih.gov/32877911/)[@park2020]\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)\n- [Beta-Adrenergic Receptors](/entities/beta-adrenergic-receptors)\n- [Memory Consolidation](/mechanisms/memory-consolidation)\n- [Neuroprotection](/therapeutics/neuroprotection)\n- [Norepinephrine](/entities/norepinephrine)\n- [Formoterol](/therapeutics/formoterol)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)\n- [UniProt: ADRB2](https://www.uniprot.org/uniprotkb/P07550)\n- [Ensembl: ADRB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252)\n- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)\n- [OMIM: ADRB2](https://omim.org/entry/109630)\n- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)\n",
  "entity_type": "gene"
}

{
  "content_md": "<div class=\"infobox infobox-gene\">\n  <table>\n    <tr><th colspan=\"2\" style=\"background:#4477AA; color:white;\">ADRB2</th></tr>\n    <tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>\n    <tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>\n    <tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>\n    <tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>\n    <tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>\n    <tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>\n    <tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>\n    <tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>\n  </table>\n</div>\n\n## Overview\n\n**ADRB2** encodes the **β2-adrenergic receptor** (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].\n\nThe β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].\n\n## Molecular Biology and Structure\n\n### Gene Organization\n\nThe ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:\n\n- **TATA box**: Core promoter element\n- **CRE elements**: cAMP response elements for regulated expression\n- **AP-1 sites**: Responsive to growth factors and cytokines\n- **GRE**: Glucocorticoid response elements\n- **NF-κB elements**: Allows inflammatory regulation\n\nMultiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].\n\n### Protein Structure\n\nThe β2-adrenergic receptor has classical GPCR architecture:\n\n- **N-terminal extracellular domain** (1-39 aa): Contains two N-linked glycosylation sites\n- **Transmembrane domains** (TM1-TM7): Seven α-helices forming the ligand-binding pocket\n- **Extracellular loops** (ECL1-ECL3): ECL2 contains a conserved disulfide bond\n- **Intracellular loops** (ICL1-ICL3): ICL3 is the primary G protein coupling domain\n- **C-terminal tail** (342-413 aa): Contains serine/threonine phosphorylation sites\n\nThe ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:\n- Asp113 in TM3 (counterion for catecholamine amine)\n- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)\n- Phe282 (hydrophobic interactions with aromatic ring)\n\n### Splice Variants\n\nMultiple splice variants of ADRB2 have been described:\n- **β2-AR1**: Full-length 413 aa (predominant)\n- **β2-AR2**: Alternative C-terminus\n- **Truncated variants**: May have distinct signaling properties\n\n## Signaling Pathways\n\n### Primary Gs-cAMP Pathway\n\nUpon agonist binding:\n\n1. **Conformational change** activates Gs protein\n2. **Gαs-GTP** stimulates adenylyl cyclase\n3. **cAMP production** increases\n4. **PKA activation** leads to substrate phosphorylation\n5. **Physiological effects** on muscle relaxation, glycogenolysis, gene transcription\n\n### Alternative Gi/o Coupling\n\nIn some cell types, β2-AR couples to Gi/o:\n- **Inhibition of adenylyl cyclase** reduces cAMP\n- **βγ subunits** activate PI3K pathways\n- **Cell-type specificity** determines coupling preference\n\n### β-Arrestin Pathways\n\nβ2-AR signals through β-arrestins independently of G proteins:\n\n- **ERK1/2 activation** via β-arrestin scaffolds\n- **Akt activation** through similar mechanisms\n- **Receptor internalization** and recycling\n- **Biased signaling** potential for drug design\n\n### Receptor Dynamics\n\nβ2-AR exhibits unique properties:\n\n- **Constitutive activity**: Some basal signaling without agonist\n- **Inverse agonism**: Some ligands reduce baseline activity\n- **Allosteric modulators**: Bind at distinct sites\n- **Oligomerization**: May form heteromers with other GPCRs\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\n#### Memory Consolidation\n\nβ2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:\n\n- **Hippocampal LTP**: β2-AR activation enhances long-term potentiation\n- **Memory enhancement**: Agonists improve consolidation in multiple paradigms\n- **cAMP/PKA/CREB pathway**: Required for consolidation effects\n- **Time window**: Effects greatest during post-training period\n\nThe noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.\n\n#### Amyloid Pathology\n\nβ2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:\n\n- **APP processing**: cAMP can influence α-secretase activity\n- **Aβ production**: Effects are context-dependent\n- **Synaptic protection**: β2-AR activation protects against Aβ-induced synaptic dysfunction\n- **Neuronal survival**: Anti-apoptotic signaling through PI3K/Akt\n\n#### Neuroinflammation\n\nβ2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:\n\n- **Microglial inhibition**: β2-AR activation reduces pro-inflammatory cytokine release\n- **TNF-α suppression**: Reduces microglial activation\n- **IL-1β and IL-6**: Suppressed by β2-agonists\n- **Therapeutic potential**: Reduces neuroinflammation in AD models\n\n#### Genetic Associations\n\nSeveral studies link ADRB2 variants to AD risk[@mittal2017]:\n\n- **Functional polymorphisms** may alter receptor signaling\n- **Population-specific effects** observed in different cohorts\n- **Gene-environment interactions** with lifestyle factors\n\n### Parkinson's Disease\n\n#### Neuroprotection\n\nβ2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:\n\n- **Dopaminergic neuron survival**: Protects against MPTP and 6-OHDA toxicity\n- **α-Synuclein effects**: May reduce aggregation or toxicity\n- **Anti-apoptotic signaling**: Through cAMP/PKA and PI3K pathways\n- **Anti-inflammatory**: Microglial suppression\n\n#### Clinical Trials\n\nβ2-agonists are being investigated for PD:\n\n- **Formoterol**: Long-acting β2-agonist in clinical trials\n- **Safety profile**: Generally well-tolerated\n- **CNS penetration**: A challenge for some compounds\n\n#### Autonomic Function\n\nβ2-AR contributes to autonomic regulation:\n\n- **Cardiac effects**: Modulates heart rate and contractility\n- **Blood pressure**: Influences vascular tone\n- **PD autonomic dysfunction**: Relevant to non-motor symptoms\n\n### Stroke and Cerebral Ischemia\n\nβ2-AR activation provides neuroprotection in stroke models[@park2020]:\n\n- **Infarct reduction**: Reduces cerebral infarction\n- **Anti-apoptotic**: Promotes neuronal survival\n- **Anti-inflammatory**: Reduces post-ischemic inflammation\n- **Angiogenesis**: May promote recovery\n\n### Mood Disorders\n\nThe β2-adrenergic system is relevant to depression:\n\n- **β2-AR downregulation**: Seen in depression\n- **Antidepressant effects**: Some antidepressants affect β2-AR signaling\n- **Therapeutic targeting**: β2-agonists have been explored\n\n## Expression Pattern\n\n### Central Nervous System\n\nIn the brain, β2-AR is expressed in:\n\n- **Hippocampus**: CA1-CA3 pyramidal cells, dentate gyrus granule cells\n- **Cerebral cortex**: Pyramidal neurons in all layers\n- **Cerebellum**: Purkinje cells and granule cells\n- **Amygdala**: Principal neurons\n- **Hypothalamus**: Regulatory neurons\n- **Basal forebrain**: Cholinergic projection neurons\n\n### Peripheral Tissues\n\nHighest peripheral expression:\n\n- **Lungs**: Bronchial smooth muscle (primary site)\n- **Heart**: Cardiac myocytes\n- **Liver**: Hepatocytes\n- **Skeletal muscle**: Muscle fibers\n- **Adipose tissue**: Brown and white adipocytes\n\n### Subcellular Localization\n\n- **Plasma membrane**: Primary location\n- **Endosomal compartments**: Internalized receptors\n- **Nucleus**: Some nuclear localization reported\n\n## Therapeutic Implications\n\n### Respiratory Diseases\n\nβ2-AR agonists are first-line treatments:\n\n| Drug | Type | Half-life | Clinical Use |\n|------|------|-----------|--------------|\n| Albuterol | SABA | 4-6 hours | Acute asthma |\n| Salmeterol | LABA | 12 hours | Maintenance asthma |\n| Formoterol | LABA | 12 hours | Asthma, COPD |\n| Indacaterol | LABA | 24 hours | COPD maintenance |\n\n### Neurodegeneration\n\nTherapeutic strategies include:\n\n1. **Brain-penetrant agonists**: Formoterol, arformoterol\n2. **β-arrestin biased ligands**: G protein-independent effects\n3. **Allosteric modulators**: Increase agonist potency\n4. **Combination approaches**: With cholinesterase inhibitors\n\n### Cardiovascular\n\nβ2-AR agonists have limited cardiac use:\n\n- **Acute decompensation**: Rarely used due to β1 effects\n- **Peripheral vasodilation**: Some β2-agonists cause hypotension\n- **Safety concerns**: Tremor and tachycardia\n\n## Animal Models\n\n### Genetic Models\n\n- **Adrb2 knockout mice**: Viable with respiratory and metabolic phenotypes\n- **Transgenic overexpression**: Tissue-specific models\n- **Humanized mice**: For drug testing\n\n### Phenotypes\n\n- **Respiratory**: Altered bronchial responsiveness\n- **Metabolic**: Changes in glycogen metabolism\n- **Cardiac**: Mild cardiac phenotypes\n- **Behavioral**: Altered stress responses\n\n### Disease Models\n\nTested in:\n- MPTP-induced parkinsonism\n- 6-OHDA lesion models\n- Transgenic AD models\n- Cerebral ischemia models\n\n## Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Epinephrine<br/>Norepinephrine\"] --> B[\"β2-Adrenergic Receptor\"]\n    B --> C1[\"Gs Protein<br/>Coupling\"]\n    B --> C2[\"Gi Protein<br/>Coupling\"]\n    B --> C3[\"β-Arrestin<br/>Pathway\"]\n\n    C1 --> D1[\"Adenylyl Cyclase<br/>up\"]\n    C1 --> D1\n    D1 --> E1[\"cAMP<br/>up\"]\n    E1 --> F1[\"PKA<br/>Activation\"]\n\n    F1 --> G1[\"CREB<br/>Phosphorylation\"]\n    F1 --> G2[\"Synaptic<br/>Plasticity\"]\n    F1 --> G3[\"Gene<br/>Transcription\"]\n    F1 --> G4[\"Anti-inflammatory<br/>Response\"]\n\n    C2 --> D2[\"Adenylyl Cyclase<br/>down\"]\n    D2 --> E2[\"cAMP<br/>down\"]\n    E2 --> F2[\"betagamma -> PI3K/Akt\"]\n\n    C3 --> D3[\"β-Arrestin<br/>Scaffold\"]\n    D3 --> E3[\"ERK1/2<br/>Activation\"]\n    D3 --> F3[\"Akt<br/>Activation\"]\n\n    G1 --> H[\"Memory<br/>Consolidation\"]\n    G2 --> H\n    G3 --> I[\"Neuronal<br/>Survival\"]\n    G4 --> J[\"Neuroprotection\"]\n\n    style A fill:#0a1929,stroke:#333\n    style B fill:#0a1929,stroke:#333\n    style H fill:#0e2e10,stroke:#333\n    style I fill:#0e2e10,stroke:#333\n    style J fill:#0e2e10,stroke:#333\n```\n\n## Key Publications\n\n1. [Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation](https://pubmed.ncbi.nlm.nih.gov/24790844/)[@lefkowitz2014]\n2. [Moreau et al., 2018 - Formoterol rescues memory in AD models](https://pubmed.ncbi.nlm.nih.gov/29686311/)[@formoterol2018]\n3. [Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/30626698/)[@birmingham2019]\n4. [Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors](https://pubmed.ncbi.nlm.nih.gov/17291618/)[@galandrin2007]\n5. [Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization](https://pubmed.ncbi.nlm.nih.gov/27029639/)[@nichols2016]\n6. [Ibayashi et al., 2019 - Beta2-AR signaling in glial cells](https://pubmed.ncbi.nlm.nih.gov/31297657/)[@ibayashi2019]\n7. [Mittal et al., 2017 - ADRB2 polymorphisms and AD risk](https://pubmed.ncbi.nlm.nih.gov/28145406/)[@mittal2017]\n8. [Yan et al., 2019 - Beta2-agonists for PD disease modification](https://pubmed.ncbi.nlm.nih.gov/31154832/)[@yan2019]\n9. [Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/29488493/)[@wang2018]\n10. [Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production](https://pubmed.ncbi.nlm.nih.gov/28222568/)[@chen2017]\n11. [Yang et al., 2016 - Beta2-AR and neuroinflammation in AD](https://pubmed.ncbi.nlm.nih.gov/27117268/)[@yang2016]\n12. [Liu et al., 2018 - Beta2-AR in PD models](https://pubmed.ncbi.nlm.nih.gov/29604376/)[@liu2018]\n13. [Xiao et al., 2019 - Beta-adrenergic signaling in the heart](https://pubmed.ncbi.nlm.nih.gov/31788967/)[@xiao2019]\n14. [Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection](https://pubmed.ncbi.nlm.nih.gov/32877911/)[@park2020]\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)\n- [Beta-Adrenergic Receptors](/entities/beta-adrenergic-receptors)\n- [Memory Consolidation](/mechanisms/memory-consolidation)\n- [Neuroprotection](/therapeutics/neuroprotection)\n- [Norepinephrine](/entities/norepinephrine)\n- [Formoterol](/therapeutics/formoterol)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)\n- [UniProt: ADRB2](https://www.uniprot.org/uniprotkb/P07550)\n- [Ensembl: ADRB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252)\n- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)\n- [OMIM: ADRB2](https://omim.org/entry/109630)\n- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)\n",
  "entity_type": "gene"
}

{
  "content_md": "<div class=\"infobox infobox-gene\">\n  <table>\n    <tr><th colspan=\"2\" style=\"background:#4477AA; color:white;\">ADRB2</th></tr>\n    <tr><td><strong>Full Name</strong></td><td>Beta-2 Adrenergic Receptor</td></tr>\n    <tr><td><strong>Gene Symbol</strong></td><td>ADRB2</td></tr>\n    <tr><td><strong>Chromosomal Location</strong></td><td>5q31-q32</td></tr>\n    <tr><td><strong>NCBI Gene ID</strong></td><td>154</td></tr>\n    <tr><td><strong>OMIM ID</strong></td><td>109630</td></tr>\n    <tr><td><strong>Ensembl ID</strong></td><td>ENSG00000169252</td></tr>\n    <tr><td><strong>UniProt ID</strong></td><td>P07550</td></tr>\n    <tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Asthma, COPD, Heart Failure</td></tr>\n  </table>\n</div>\n\n## Overview\n\n**ADRB2** encodes the **β2-adrenergic receptor** (β2-AR), a G-protein coupled receptor that mediates the effects of epinephrine and norepinephrine. While sharing structural homology with β1-AR, β2-AR has distinct pharmacological properties, tissue distribution, and physiological functions. In the central nervous system, β2-AR plays crucial roles in memory consolidation, synaptic plasticity, and neuroprotection, making it highly relevant to neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@lefkowitz2014][@formoterol2018].\n\nThe β2-AR primarily couples to Gs proteins, stimulating adenylyl cyclase and increasing cAMP, similar to β1-AR. However, it can also couple to Gi/o proteins in certain cell types, allowing for more diverse signaling. Additionally, β2-AR exhibits unique properties including ligand-independent constitutive activity and the ability to signal through β-arrestin-biased pathways[@galandrin2007][@nichols2016].\n\n## Molecular Biology and Structure\n\n### Gene Organization\n\nThe ADRB2 gene is located on chromosome 5q31-q32 and consists of 4 exons spanning approximately 1.8 kilobases. The single coding exon encodes a 413-amino acid protein. The gene promoter contains:\n\n- **TATA box**: Core promoter element\n- **CRE elements**: cAMP response elements for regulated expression\n- **AP-1 sites**: Responsive to growth factors and cytokines\n- **GRE**: Glucocorticoid response elements\n- **NF-κB elements**: Allows inflammatory regulation\n\nMultiple transcription start sites enable complex regulation of expression across tissues[@johnson2015].\n\n### Protein Structure\n\nThe β2-adrenergic receptor has classical GPCR architecture:\n\n- **N-terminal extracellular domain** (1-39 aa): Contains two N-linked glycosylation sites\n- **Transmembrane domains** (TM1-TM7): Seven α-helices forming the ligand-binding pocket\n- **Extracellular loops** (ECL1-ECL3): ECL2 contains a conserved disulfide bond\n- **Intracellular loops** (ICL1-ICL3): ICL3 is the primary G protein coupling domain\n- **C-terminal tail** (342-413 aa): Contains serine/threonine phosphorylation sites\n\nThe ligand-binding pocket accommodates catecholamines with high affinity. Key structural features include:\n- Asp113 in TM3 (counterion for catecholamine amine)\n- Ser203, Ser204, Ser207 (hydrogen bond donors for catechol hydroxyls)\n- Phe282 (hydrophobic interactions with aromatic ring)\n\n### Splice Variants\n\nMultiple splice variants of ADRB2 have been described:\n- **β2-AR1**: Full-length 413 aa (predominant)\n- **β2-AR2**: Alternative C-terminus\n- **Truncated variants**: May have distinct signaling properties\n\n## Signaling Pathways\n\n### Primary Gs-cAMP Pathway\n\nUpon agonist binding:\n\n1. **Conformational change** activates Gs protein\n2. **Gαs-GTP** stimulates adenylyl cyclase\n3. **cAMP production** increases\n4. **PKA activation** leads to substrate phosphorylation\n5. **Physiological effects** on muscle relaxation, glycogenolysis, gene transcription\n\n### Alternative Gi/o Coupling\n\nIn some cell types, β2-AR couples to Gi/o:\n- **Inhibition of adenylyl cyclase** reduces cAMP\n- **βγ subunits** activate PI3K pathways\n- **Cell-type specificity** determines coupling preference\n\n### β-Arrestin Pathways\n\nβ2-AR signals through β-arrestins independently of G proteins:\n\n- **ERK1/2 activation** via β-arrestin scaffolds\n- **Akt activation** through similar mechanisms\n- **Receptor internalization** and recycling\n- **Biased signaling** potential for drug design\n\n### Receptor Dynamics\n\nβ2-AR exhibits unique properties:\n\n- **Constitutive activity**: Some basal signaling without agonist\n- **Inverse agonism**: Some ligands reduce baseline activity\n- **Allosteric modulators**: Bind at distinct sites\n- **Oligomerization**: May form heteromers with other GPCRs\n\n## Role in Neurodegenerative Diseases\n\n### Alzheimer's Disease\n\n#### Memory Consolidation\n\nβ2-AR plays a critical role in memory consolidation[@lefkowitz2014][@wang2018]:\n\n- **Hippocampal LTP**: β2-AR activation enhances long-term potentiation\n- **Memory enhancement**: Agonists improve consolidation in multiple paradigms\n- **cAMP/PKA/CREB pathway**: Required for consolidation effects\n- **Time window**: Effects greatest during post-training period\n\nThe noradrenergic system from the locus coeruleus modulates memory through β2-AR, particularly for emotionally salient information.\n\n#### Amyloid Pathology\n\nβ2-AR signaling affects APP processing and Aβ toxicity[@chen2017]:\n\n- **APP processing**: cAMP can influence α-secretase activity\n- **Aβ production**: Effects are context-dependent\n- **Synaptic protection**: β2-AR activation protects against Aβ-induced synaptic dysfunction\n- **Neuronal survival**: Anti-apoptotic signaling through PI3K/Akt\n\n#### Neuroinflammation\n\nβ2-AR has potent anti-inflammatory effects in the brain[@yang2016][@ibayashi2019]:\n\n- **Microglial inhibition**: β2-AR activation reduces pro-inflammatory cytokine release\n- **TNF-α suppression**: Reduces microglial activation\n- **IL-1β and IL-6**: Suppressed by β2-agonists\n- **Therapeutic potential**: Reduces neuroinflammation in AD models\n\n#### Genetic Associations\n\nSeveral studies link ADRB2 variants to AD risk[@mittal2017]:\n\n- **Functional polymorphisms** may alter receptor signaling\n- **Population-specific effects** observed in different cohorts\n- **Gene-environment interactions** with lifestyle factors\n\n### Parkinson's Disease\n\n#### Neuroprotection\n\nβ2-AR activation provides neuroprotection in PD models[@birmingham2019][@yan2019]:\n\n- **Dopaminergic neuron survival**: Protects against MPTP and 6-OHDA toxicity\n- **α-Synuclein effects**: May reduce aggregation or toxicity\n- **Anti-apoptotic signaling**: Through cAMP/PKA and PI3K pathways\n- **Anti-inflammatory**: Microglial suppression\n\n#### Clinical Trials\n\nβ2-agonists are being investigated for PD:\n\n- **Formoterol**: Long-acting β2-agonist in clinical trials\n- **Safety profile**: Generally well-tolerated\n- **CNS penetration**: A challenge for some compounds\n\n#### Autonomic Function\n\nβ2-AR contributes to autonomic regulation:\n\n- **Cardiac effects**: Modulates heart rate and contractility\n- **Blood pressure**: Influences vascular tone\n- **PD autonomic dysfunction**: Relevant to non-motor symptoms\n\n### Stroke and Cerebral Ischemia\n\nβ2-AR activation provides neuroprotection in stroke models[@park2020]:\n\n- **Infarct reduction**: Reduces cerebral infarction\n- **Anti-apoptotic**: Promotes neuronal survival\n- **Anti-inflammatory**: Reduces post-ischemic inflammation\n- **Angiogenesis**: May promote recovery\n\n### Mood Disorders\n\nThe β2-adrenergic system is relevant to depression:\n\n- **β2-AR downregulation**: Seen in depression\n- **Antidepressant effects**: Some antidepressants affect β2-AR signaling\n- **Therapeutic targeting**: β2-agonists have been explored\n\n## Expression Pattern\n\n### Central Nervous System\n\nIn the brain, β2-AR is expressed in:\n\n- **Hippocampus**: CA1-CA3 pyramidal cells, dentate gyrus granule cells\n- **Cerebral cortex**: Pyramidal neurons in all layers\n- **Cerebellum**: Purkinje cells and granule cells\n- **Amygdala**: Principal neurons\n- **Hypothalamus**: Regulatory neurons\n- **Basal forebrain**: Cholinergic projection neurons\n\n### Peripheral Tissues\n\nHighest peripheral expression:\n\n- **Lungs**: Bronchial smooth muscle (primary site)\n- **Heart**: Cardiac myocytes\n- **Liver**: Hepatocytes\n- **Skeletal muscle**: Muscle fibers\n- **Adipose tissue**: Brown and white adipocytes\n\n### Subcellular Localization\n\n- **Plasma membrane**: Primary location\n- **Endosomal compartments**: Internalized receptors\n- **Nucleus**: Some nuclear localization reported\n\n## Therapeutic Implications\n\n### Respiratory Diseases\n\nβ2-AR agonists are first-line treatments:\n\n| Drug | Type | Half-life | Clinical Use |\n|------|------|-----------|--------------|\n| Albuterol | SABA | 4-6 hours | Acute asthma |\n| Salmeterol | LABA | 12 hours | Maintenance asthma |\n| Formoterol | LABA | 12 hours | Asthma, COPD |\n| Indacaterol | LABA | 24 hours | COPD maintenance |\n\n### Neurodegeneration\n\nTherapeutic strategies include:\n\n1. **Brain-penetrant agonists**: Formoterol, arformoterol\n2. **β-arrestin biased ligands**: G protein-independent effects\n3. **Allosteric modulators**: Increase agonist potency\n4. **Combination approaches**: With cholinesterase inhibitors\n\n### Cardiovascular\n\nβ2-AR agonists have limited cardiac use:\n\n- **Acute decompensation**: Rarely used due to β1 effects\n- **Peripheral vasodilation**: Some β2-agonists cause hypotension\n- **Safety concerns**: Tremor and tachycardia\n\n## Animal Models\n\n### Genetic Models\n\n- **Adrb2 knockout mice**: Viable with respiratory and metabolic phenotypes\n- **Transgenic overexpression**: Tissue-specific models\n- **Humanized mice**: For drug testing\n\n### Phenotypes\n\n- **Respiratory**: Altered bronchial responsiveness\n- **Metabolic**: Changes in glycogen metabolism\n- **Cardiac**: Mild cardiac phenotypes\n- **Behavioral**: Altered stress responses\n\n### Disease Models\n\nTested in:\n- MPTP-induced parkinsonism\n- 6-OHDA lesion models\n- Transgenic AD models\n- Cerebral ischemia models\n\n## Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Epinephrine<br/>Norepinephrine\"] --> B[\"beta2-Adrenergic Receptor\"]\n    B --> C1[\"Gs Protein<br/>Coupling\"]\n    B --> C2[\"Gi Protein<br/>Coupling\"]\n    B --> C3[\"beta-Arrestin<br/>Pathway\"]\n\n    C1 --> D1[\"Adenylyl Cyclase<br/>up\"]\n    C1 --> D1\n    D1 --> E1[\"cAMP<br/>up\"]\n    E1 --> F1[\"PKA<br/>Activation\"]\n\n    F1 --> G1[\"CREB<br/>Phosphorylation\"]\n    F1 --> G2[\"Synaptic<br/>Plasticity\"]\n    F1 --> G3[\"Gene<br/>Transcription\"]\n    F1 --> G4[\"Anti-inflammatory<br/>Response\"]\n\n    C2 --> D2[\"Adenylyl Cyclase<br/>down\"]\n    D2 --> E2[\"cAMP<br/>down\"]\n    E2 --> F2[\"betagamma -> PI3K/Akt\"]\n\n    C3 --> D3[\"beta-Arrestin<br/>Scaffold\"]\n    D3 --> E3[\"ERK1/2<br/>Activation\"]\n    D3 --> F3[\"Akt<br/>Activation\"]\n\n    G1 --> H[\"Memory<br/>Consolidation\"]\n    G2 --> H\n    G3 --> I[\"Neuronal<br/>Survival\"]\n    G4 --> J[\"Neuroprotection\"]\n\n    style A fill:#0a1929,stroke:#333\n    style B fill:#0a1929,stroke:#333\n    style H fill:#0e2e10,stroke:#333\n    style I fill:#0e2e10,stroke:#333\n    style J fill:#0e2e10,stroke:#333\n```\n\n## Key Publications\n\n1. [Lefkowitz, 2014 - Beta-adrenergic receptors and memory consolidation](https://pubmed.ncbi.nlm.nih.gov/24790844/)[@lefkowitz2014]\n2. [Moreau et al., 2018 - Formoterol rescues memory in AD models](https://pubmed.ncbi.nlm.nih.gov/29686311/)[@formoterol2018]\n3. [Kim et al., 2019 - Beta2-AR agonist protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/30626698/)[@birmingham2019]\n4. [Galandrin et al., 2007 - Constitutively active beta-adrenergic receptors](https://pubmed.ncbi.nlm.nih.gov/17291618/)[@galandrin2007]\n5. [Nichols et al., 2016 - Beta2-AR phosphorylation and desensitization](https://pubmed.ncbi.nlm.nih.gov/27029639/)[@nichols2016]\n6. [Ibayashi et al., 2019 - Beta2-AR signaling in glial cells](https://pubmed.ncbi.nlm.nih.gov/31297657/)[@ibayashi2019]\n7. [Mittal et al., 2017 - ADRB2 polymorphisms and AD risk](https://pubmed.ncbi.nlm.nih.gov/28145406/)[@mittal2017]\n8. [Yan et al., 2019 - Beta2-agonists for PD disease modification](https://pubmed.ncbi.nlm.nih.gov/31154832/)[@yan2019]\n9. [Wang et al., 2018 - Beta2-AR and hippocampal synaptic plasticity](https://pubmed.ncbi.nlm.nih.gov/29488493/)[@wang2018]\n10. [Chen et al., 2017 - Beta2-AR modulation of amyloid-beta production](https://pubmed.ncbi.nlm.nih.gov/28222568/)[@chen2017]\n11. [Yang et al., 2016 - Beta2-AR and neuroinflammation in AD](https://pubmed.ncbi.nlm.nih.gov/27117268/)[@yang2016]\n12. [Liu et al., 2018 - Beta2-AR in PD models](https://pubmed.ncbi.nlm.nih.gov/29604376/)[@liu2018]\n13. [Xiao et al., 2019 - Beta-adrenergic signaling in the heart](https://pubmed.ncbi.nlm.nih.gov/31788967/)[@xiao2019]\n14. [Park et al., 2020 - Beta2-AR agonists for stroke neuroprotection](https://pubmed.ncbi.nlm.nih.gov/32877911/)[@park2020]\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Adrenergic Signaling Pathway](/mechanisms/adrenergic-signaling)\n- [Beta-Adrenergic Receptors](/entities/beta-adrenergic-receptors)\n- [Memory Consolidation](/mechanisms/memory-consolidation)\n- [Neuroprotection](/therapeutics/neuroprotection)\n- [Norepinephrine](/entities/norepinephrine)\n- [Formoterol](/therapeutics/formoterol)\n- [Hippocampus](/brain-regions/hippocampus)\n\n## External Links\n\n- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)\n- [UniProt: ADRB2](https://www.uniprot.org/uniprotkb/P07550)\n- [Ensembl: ADRB2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169252)\n- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197)\n- [OMIM: ADRB2](https://omim.org/entry/109630)\n- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)\n",
  "entity_type": "gene"
}